A comparative study of the reversal effect of sugammadex and neostigmine on muscle relaxation and postoperative pulmonary complications in patients undergoing radical resection of lung cancer

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039572

Enrollment

Unknown

Registered

2020-11-01

Start date

2021-01-01

Completion date

Unknown

Last updated

2021-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

sugammadex:sugammadex

neostigmine:neostigmine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Adult patients (>=18 years old); (2) had no metastasis of other organs and lymph nodes by pathological biopsy; (3) received endotracheal intubation general anesthesia; (4) used steroidal non-depolarizing muscle relaxants (vecuronium or rocuronium); (5) American Association of Anesthesiologists (ASA) grade I-III; (6) the vital signs of the patients were stable (including body temperature, heart rate, respiration, blood pressure).

Exclusion criteria

Exclusion criteria: (1) suffering from contraindication of neuromuscular block; (2) severe abnormality of heart, liver and kidney function; (3) allergy to sugammadex or neostigmine.

Design outcomes

Primary

Measure	Time frame
Muscle relaxation recovery time;Postoperative pulmonary complications;	—

Secondary

Measure	Time frame
blood pressure;heart rate;	—

Countries

China

Contacts

Public ContactJinfeng Ding

Taizhou Hospital of Zhejiang Province

dingjf@enzemed.com+86 13515861771

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026